Similarly, although PD-L1 IHC is another important anti-PD-(L)1 therapy biomarker, particularly in first-line treatment decisions, in practice it does not represent a pan tumor biomarker, but rather a series of tumor type–specific biomarkers with various antibodies, staining platforms, PD-L1–expressing cells included in scoring algorithms, and cutoffs (9–19). Here, CD274 is linked to neoplasm.